Nektar Therapeutics (NKTR) Accounts Payables (2010 - 2026)

Nektar Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $10.0 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 43.78% year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $10.0 million (down 43.78% YoY), while the FY2025 annual figure was $10.8 million, down 6.83% from the prior year.
• Accounts Payables was $10.0 million for Q1 2026 at Nektar Therapeutics, down from $10.8 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $17.8 million in Q1 2025 to a low of $2.6 million in Q2 2023.
• Historically, Accounts Payables has averaged $9.8 million across 5 years, with a median of $10.0 million in 2026.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables tumbled 78.79% in 2023, then soared 160.86% in 2024.
• A 5-year view of Accounts Payables shows it stood at $13.0 million in 2022, then declined by 24.13% to $9.8 million in 2023, then advanced by 17.38% to $11.6 million in 2024, then fell by 6.83% to $10.8 million in 2025, then dropped by 6.91% to $10.0 million in 2026.
• The last three Accounts Payables figures came in at $10.0 million (Q1 2026), $10.8 million (Q4 2025), and $15.6 million (Q3 2025), per Business Quant data.